secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-04-08T23:59:59+00:00
Accession:  0001213900-25-029914
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports record Q1 2025 sales of $8.1M, up 11% YoY
----------------------------------------------------------

- Preliminary unaudited product sales for Q1 2025: $8.1M, up 11% from $7.3M in Q1 2024.
- All-time quarterly sales record; six-month ($15.8M) and twelve-month ($27.3M) periods also record.
- Order backlog reduced to $4.0M as of March 31, 2025, from $4.4M at Dec 31, 2024.
- Annualized Q1 sales were approximately 108% of estimated $30M annual capacity.
- NADA submission for Re-Tain progressing; critical path remains inspection at contract manufacturer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390025029914/0001213900-25-029914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390025029914/ea0237552-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-029914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer